The World Health Organization is on its way to supporting medicine for weight loss to treat obesity

A draft guideline from the World Health Organization has shown that it would recommend using weight loss medicines to treat obesity in adults and to encourage states to take the issue of obesity as a chronic disease seriously. The WHO expert committee concluded that the general GLP-1 medicine, which depended on the simulation of the Bealagon-1 peptide, which was ‘Novo Nordisk’ and ‘Eli Lily’, was the first to be part of the solution to treat obesity for patients who were BMI (BMI) at 30 or more, In the draft lines published on the Internet and open to consultation until September 27, the World Health Organization said that addressing the problem of obesity is often formed on the basis of outdated old views that represent it as a lifestyle problem. But the organization said instead that the problem of obesity is “a chronic, aggravated and repeated disease” affects more than a billion people around the world in both high and low income countries and contributes to millions of deaths that could be avoided. The UN Organization recommended for the first time to use this medicine to treat obesity, describing it as an important step in developing a global standard of care. The organization is currently working on setting up separate instructions for treating children and adolescents. The WHO’s guidelines apply to those who have a body mass index above only 30, but in some high income countries, such as the United States, this medication is also recommended for those who have a body mass index between 27 and 30 and suffer from at least one medical condition linked to weight. Earlier this month, the World Health Organization did not reach the extent of the addition of this medicine to treat obesity on the basic medicine list, a separate list that includes medicines that should be available in all industry health systems. But it has already added it to Type 2 diabetics, the disease that businesses have developed this medication to treat in the first place, when combined with another health condition. The organization added that it indicates that patients who will benefit more than these expensive treatments, note that high prices limit the possibility of obtaining medicines in low and medium -income countries.